{"Clinical Trial ID": "NCT00429104", "Intervention": ["INTERVENTION 1:", "HER2+ Metastatic breast cancer", "Herceptin 4 mg/kg intravenously (IV) More than 90 minutes + granulocyte-macrophagus colony stimulation factor (GM-CSF) 250 mcg/m^2 subcutaneously"], "Eligibility": ["Incorporation criteria:", "- Histological confirmation of invasive breast carcinoma.", "- HER-2/neu overexpression: 3+ by immunohistochemical staining or in situ fluorescence hybridization (FISH) (+).", "Stage IV breast cancer with measurable disease.", "* Patients receiving progressive disease after Herceptin or Herceptin chemotherapy alone. No more than two treatments containing Herceptin.", "Performance status of Zubrod 0 or 1.", "adequate haematological parameters (white blood cells-WBC > 3000/mm3, platelet count > 100,000/mm3), adequate renal function (serum creatinine < 2.0 mg/dl), adequate hepatic function (total bilirubin, aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT or SGPT) < 3 x normal).", "- Exclusion criteria:", "- Active brain metastasis.", "No measurable disease at time of registration (e.g. bone only, leptomenal disease alone or pleural effusion alone).", "More than 2 treatments containing herceptin in metastatic breast cancer.", "\u2022 Known history of HIV seropositivity.", "- Chronic active hepatitis or cirrhosis.", "A symptomatic lung disease.", "Use of nonsteroidal analgesic anti-inflammatory steroids or Cox-2 inhibitors 1 week prior to registration."], "Results": ["Performance measures:", "Number of participants who received a tumour response (stable illness)", "Number of participants with a response defined as a stable or better disease using the solid tumour response assessment criteria (RECIST) during the second month of evaluation.", "Time limit: 2 months", "Results 1:", "Title of the arm/group: HER2+ Metastatic breast cancer", "Description of the arm/group: Herceptin 4 mg/kg intravenously (IV) More than 90 minutes + granulocyte-macrophagus colony stimulation factor (GM-CSF) 250 mcg/m^2 subcutaneously", "Total number of participants analysed: 17", "Type of measurement: Number", "Unit of measurement: participants 5"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/17 (0.00 per cent)"]}